Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies

Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12:316–28.

CAS  PubMed  Article  Google Scholar 

dos Santos Coura R, Nardi NB. A role for adeno-associated viral vectors in gene therapy. Genet Mol Biol. 2008;31:1–11.

Article  Google Scholar 

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359:eaan4672.

Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng. 2015;17:63–89. 101146/annurev-bioeng-071813-104938.

Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464–88.

CAS  PubMed  Article  Google Scholar 

Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:1–24.

Article  CAS  Google Scholar 

Naso MF, Tomkowicz B, Perry WL III, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. Biodrugs. 2017;31:317.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Shirley JL, Jong YP, de, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28:709–22.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kumar SR, Markusic DM, Biswas M, High KA, Herzog RW. Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev. 2016;3:16034.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Rose JA, Hoggan MD, Shatkin AJ. Nucleic acid from an adeno-associated virus: chemical and physical studies. Proc Natl Acad Sci USA 1966;56:86–92.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21:583.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ogden PJ, Kelsic ED, Sinai S, Church GM. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science. 2019;366:1139–43.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Maurer AC, Cepeda Diaz AK, Vandenberghe LH. Residues on adeno-associated virus capsid lumen dictate interactions and compatibility with the assembly-activating protein. J Virol. 2019;93:2013–31.

Article  Google Scholar 

Cao M, You H, Hermonat PL. The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS One. 2014;9:e104596.

PubMed  PubMed Central  Article  Google Scholar 

Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bennett A, Patel S, Mietzsch M, Jose A, Lins-Austin B, Yu JC, et al. Thermal stability as a determinant of AAV serotype identity. Mol Ther Methods Clin Dev. 2017;6:171–82.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015;47:1187–93.

CAS  PubMed  Article  Google Scholar 

Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol. 2000;74:2777.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Hamilton H, Gomos J, Berns KI, Falck-Pedersen E. Adeno-associated virus site-specific integration and AAVS1 disruption. J Virol. 2004;78:7874–82.

CAS  PubMed  PubMed Central  Article  Google Scholar 

McCarty DM, Young SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819–45.

CAS  PubMed  Article  Google Scholar 

Schnepp BC, Jensen RL, Chen C-L, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 2005;79:14793–803.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000;97:6716–21.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Earley LF, Conatser LM, Lue VM, Dobbins AL, Li C, Hirsch ML, et al. Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression. Hum Gene Ther. 2020;31:151.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ehrhardt A, Xu H, Kay MA. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol. 2003;77:7689.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Riyad JM, Weber T. Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions. Gene Ther. 2021;28:683–96.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Balakrishnan B, Jayandharan G. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther. 2014;14:86–100.

CAS  PubMed  Article  Google Scholar 

Weinmann J, Grimm D. Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes. 2017;53:707–13.

CAS  PubMed  Article  Google Scholar 

Bowles DE, McPhee SWJ, Li C, Gray SJ, Samulski JJ, Camp AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012;20:443–55.

CAS  PubMed  Article  Google Scholar 

Domenger C, Grimm D. Next-generation AAV vectors—do not judge a virus (only) by its cover. Hum Mol Genet. 2019;28:R3–14.

CAS  PubMed  Article  Google Scholar 

Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28:723.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PWL, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021;131:e143780.

Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122:23–36.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lykken EA, Shyng C, Edwards RJ, Rozenberg A, Gray SJ. Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord. 2018;10:1–10.

Article  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020;21:496–8. https://doi.org/10.1177/1524839919893361.

Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008;15:831–9.

CAS  PubMed  Article  Google Scholar 

Lee JH, Wang JH, Chen J, Li F, Edwards TL, Hewitt AW, et al. Gene therapy for visual loss: opportunities and concerns. Prog Retin Eye Res. 2019;68:31–53.

CAS  PubMed  Article  Google Scholar 

Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2006;13:241–9.

CAS  PubMed  Article  Google Scholar 

Phillips JL, Hegge J, Wolff JA, Samulski RJ, Asokan A. Systemic gene transfer to skeletal muscle using reengineered AAV vectors. Methods Mol Biol. 2011;709:141.

CAS  PubMed  PubMed Central  Article  Google Scholar 

High-dose AAV gene therapy deaths. Nat Biotechnol. 2020;38:910.

Kishimoto TK, Samulski RJ. Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’? Expert Opin Biol Ther. 2022;1–5. https://doi.org/10.1080/14712598.2022.2060737.

Mullard A. Gene therapy community grapples with toxicity issues, as pipeline matures. Nat Rev Drug Discov. 2021;20:804–5.

CAS  PubMed  Article  Google Scholar 

Duan D. Systemic delivery of adeno-associated viral vectors. Curr Opin Virol. 2016;21:16.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Clément N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3:16002.

留言 (0)

沒有登入
gif